BostonGene Announces Publication in Blood

An AI-driven imaging pipeline revolutionizes bone marrow analysis, unraveling the intricacies of hematopoiesis

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-based molecular and immune profiling solutions today announced the online publication of the manuscript, “Spatial Mapping of Human Hematopoiesis at Single Cell Resolution Reveals Aging-Associated Topographic Remodeling,” in Blood, the most cited peer-reviewed publication in the field of hematology.

In a recent collaboration, Sanjay Patel, MD, MPH, Assistant Professor of Pathology and Laboratory Medicine and Director of the Multiparametric In Situ Imaging Laboratory at Weill Cornell Medicine, collaborated with BostonGene to investigate how we look at bone marrow. Historically, limited imaging studies have been performed on bone marrow tissue due to sample heterogeneity and complex analytics. To address these challenges, the study team developed an AI-driven multiparametric end-to-end imaging pipeline, encompassing whole tissue staining, whole slide in situ imaging, and integrative image analysis. This pipeline was applied to normal clinical samples to survey changes in the topography of human hematopoiesis associated with aging, uncovering intricate relationships among the 1.5 million cells analyzed across 11 unique cell types. The study findings not only expands our understanding of bone marrow dynamics but also paves the way for future innovations in the diagnosis and treatment of blood-based diseases.

Dr. Patel emphasized the clinical significance of this innovative approach, stating, "Our versatile pipeline for multiparametric imaging and analysis of human bone marrow can allow any user to manage an unwieldy amount of data. In this proof-of-concept study we demonstrate the utility of this pipeline in revealing subtle changes in the hematopoietic topography associated with aging."

"This adaptable pipeline can be harnessed by other investigators pursuing single-cell resolution spatial investigation of bone marrow,” added Nathan Fowler, MD, Chief Medical Officer at BostonGene. “Our pipeline not only enhances our understanding of normal bone marrow but also has implications for novel diagnostic and therapeutic approaches in precision oncology, particularly for blood-based cancers."

About BostonGene Corporation

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s concierge-service model provides customized client solutions using a multi-omic approach prioritized for real-world impact to optimize standard-of-care therapies, accelerate research and provide cost-effective, measurable data-driven results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.